Insulin B (22-25)

Insulin B (22-25) (CPC catalog code ILGF-006) is a synthetic growth-factor / mitogen peptide in the growth factors category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.

Published and internal research programs use Insulin B (22-25) as a reference standard in growth factors workflows — for example, proliferation and brdu / edu assays and wound-healing and scratch-closure models. Human clinical evidence is not established.

No. Insulin B (22-25) is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.

In a growth factors workflow, Insulin B (22-25) is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. Phospho-ERK and phospho-AKT Western blots or AlphaLISA assays are the standard readouts.

Store lyophilized at −20 °C. Reconstituted stocks stable at 4 °C for up to 2 weeks. Follow your institution's standard operating procedures for handling synthetic peptides.

This kindr reference page mirrors CPC Scientific's catalog metadata for ILGF-006. The upstream reference sheet — including sequence, purity, MW, and application notes where published — is linked from the buy panel. All orders placed on kindr Peptides ship internationally under research-use terms only.

Research-grade peptides in the CPC catalog are synthesized by solid-phase peptide synthesis (SPPS), purified by preparative RP-HPLC, and characterized by analytical HPLC and mass spectrometry. Typical purity is ≥95%; certificate of analysis is available on request.